AstraZeneca reports Phase III results for Ultomiris and Sone-Ve

Phase 3UltomirisSone-VeNeutral

AI Analysis

Summary

AstraZeneca announced Phase III study results for Ultomiris in thrombotic microangiopathy following HSCT-TMA and Sone-Ve in advanced gastric and GEJ cancers. Specific efficacy or safety outcomes were not disclosed in this announcement.

Clinical Trial Data

Phase

Phase III

Importance:6/10

Sentiment:

0.00

Phase 3 resultsUltomirisSone-Vethrombotic microangiopathygastric cancer

Related Companies

$AZN

Read the original article

Published by Clinical Trials Arena on July 28, 2026 8:31 AM

Read Original